

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-69 are canceled.

70. (New) An antibody that binds human IL-13, wherein said antibody binds to an epitope comprising the sequence ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO:19).

71. (New) The antibody of claim 70, wherein the antibody comprises CDRH1, CDRH2 and CDRH3 with the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively.

72. (New) The antibody of claim 70, wherein the antibody comprises CDRL1, CDRL2 and CDRL3 with the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

73. (New) The antibody of claim 71, wherein the antibody comprises CDRL1, CDRL2 and CDRL3 with the sequences of SEQ ID NO: 99, SEQ ID NO: 104 and SEQ ID NO: 115, respectively.

74. (New) The antibody of claim 70, wherein said antibody comprises a heavy chain comprising:

(1) a CDRH1 having the amino acid sequence SEQ ID NO: 117, 118, 119, 120, 121 or 122;

(2) a CDRH2 having the amino acid sequence SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and

(3) a CDRH3 having the amino acid sequence SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.

75. (New) The antibody of claim 70, wherein said antibody comprises a heavy chain comprising a VH chain with at least 85 % identity to SEQ ID NO: 143, 145, 146, 147, 148 or 149.

76. (New) The antibody of claim 75, wherein said VH chain of said antibody has at least 95% identity to SEQ ID NO: 143, 145, 146, 147, 148 or 149.

77. (New) The antibody of claim 70, wherein said antibody comprises a light chain comprising:

(1) a CDRL1 having the amino acid sequence SEQ ID NO: 99, 100, 101, 102, or 103;

(2) a CDRL2 having the amino acid sequence SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and

(3) a CDRL3 having the amino acid sequence SEQ ID NO: 115 or 116.

78. (New) The antibody of claim 70, wherein said antibody comprises a light chain comprising a VL chain with at least 85% identity to SEQ ID NO: 142, 144 or 150.

79. (New) The antibody of claim 78, wherein said VL chain of said antibody has at least 95% identity to SEQ ID NO: 142, 144 or 150.

80. (New) The antibody of claim 70, wherein said antibody comprises a VL chain with one of the following amino acid sequences SEQ ID NO: 142, 144 or 150; and said antibody comprises a VH chain with one of the following amino acid sequences SEQ ID NO: 143, 145, 146, 147, 148 or 149.

81. (New) The antibody of any one of claims 70 to 73, wherein the antibody is an IgG antibody.

82. (New) The antibody of claim 81, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

83. (New) The antibody of any one of claims 70 to 73, wherein the antibody is humanized.

84. (New) The antibody of any one of claims 70 to 73, wherein the antibody is an antibody fragment.
85. (New) The antibody of any one of claims 70 to 73, wherein the antibody is a single chain antibody or a single domain antibody.
86. (New) A method for treating asthma in a patient, comprising administering to a patient in need thereof an effective amount of the antibody of any one of claims 70 to 80.
87. (New) A method for treating an inflammatory disease in a patient, comprising administering to a patient in need thereof an effective amount of the antibody of any one of claims 70 to 80.
88. (New) The method of claim 86, wherein the antibody is humanized.
89. (New) The method of claim 87, wherein the antibody is humanized.
90. (New) The method of claim 86, wherein the effective amount is between 0.1mg/kg and 20/mg/kg.
91. (New) The method of claim 87, wherein the effective amount is between 0.1mg/kg and 20/mg/kg.
92. (New) A pharmaceutical composition comprising the antibody of any one of claims 70 to 80.
93. (New) A pharmaceutical composition comprising the antibody of claim 83.